

#330 - Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer

Renato Cunha^a, Marta Fernandes^b, Sofia Abreu^b, Cristina Oliveira^b, João Dias^b, Sara Alves^b, Ana Rodrigues^b, Júlio Oliveira^b, Inês Pousa^b, Marta Soares^b, Isabel Azevedo^b

^aHospital do Espírito Santo de Évora, ^bInstituto Português de Oncologia do Porto

Head of Department: Prof. Doutora Deolinda Pereira






ESMO



Renato Cunha - hrcunha11@gmail.com



Real life efficacy and safety was similar to trials with ICI after progression to first-line treatment. Only ECOG-PS 0-1 was significantly associated with better survival.

Anti-PD-1 were superior to anti-PD-L1 in most efficacy parameters, presenting a strong tendency in OS. There were no clear differences between different anti-PD-1.

Longer follow-up and bigger population are needed to clarify differences between treatments.

Sentember 2019 Ettinger DS, Wood DE, Aisner DL, et al.NCCN clinical practice guidelines in oncology:Non-small cell lung cancer. Version 4.2020;May 15 2020

Borghaei H, Paz-Ares L, Horn L, et al., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015;373:1627–1639. Herbst RS, Baas P, Kim DW, et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial Lancet 2016;387:1540=1550

Rittmever A, Barlesi F, Waterkamp D, et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK); a phase 3. openlabel, multicentre randomised controlled trial, Lancet, 389(2017):255-265.

months.

progression to first-line treatment.

Objectives:

Evaluate real-life efficacy and safety. Analyze factors related with survival. Compare different treatment options.

Methods:

Retrospective observational study of patients with metastatic NSCLC treated in second or further line with ICIs, from 2015 to 2019.

Statistical analysis with Excel® and IBM SPSS software v.25[®].

OS and progression-free survival (PFS) using Kaplan-Meier curves.

Factors associated with survival using Cox regression analysis.